NDRA
ENDRA Life Sciences Inc. · NASDAQ
- Market cap
- $6.6M
52-week range44% up the range
$2.98$6.70
ENDRA Life Sciences Inc. (NDRA) is a Biotechnology: Electromedical & Electrotherapeutic Apparatus company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for NDRA, including 1 13D/G filing, 1 earnings update and 1 SEC filing. The most recent was published Nov 16, 2026.
Price$4.63+0.21 (+4.63%)
2026-08-142026-11-16
Financial highlights
Full financials- Net income, TTM
- -$5.85M
- Cash
- $1.52M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks21+50%
2026-05-242026-11-15
Mix790d
- SEC Filings5(71%)
- 13D/G1(14%)
- Earnings1(14%)
Activity · 52 weeks4427 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (NDRA) (CIK 0001681682)
- PRENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business UpdateENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the third quarter ended September 30, 2026, and provided a business update. Business Update During the third quarter of 2026, ENDRA continued to manage its operating costs while continue to develop its third-generation ultrasound product. At the same time, ENDRA is working to advance its proposed merger with Noble Africa LLC ("Noble Africa"), a subsidiary of ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes"), and managed its operating resources in anticipation of the propos
- 13D/GSEC Form SCHEDULE 13G filed by ENDRA Life Sciences Inc.SCHEDULE 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)
- SECSEC Form 425 filed by ENDRA Life Sciences Inc.425 - ENDRA Life Sciences Inc. (0001681682) (Subject)
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECSEC Form 425 filed by ENDRA Life Sciences Inc.425 - ENDRA Life Sciences Inc. (0001681682) (Subject)
- SECSEC Form 425 filed by ENDRA Life Sciences Inc.425 - ENDRA Life Sciences Inc. (0001681682) (Subject)
- SECSEC Form 425 filed by ENDRA Life Sciences Inc.425 - ENDRA Life Sciences Inc. (0001681682) (Subject)
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRASP Isotopes Issues Letter to ShareholdersDALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes", "ASPI" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, today released the following letter to shareholders from its Executive Chairman and Chief Executive Officer, Paul Mann. Dear Fellow Shareholder, As we prepare to announce financial results for the second quarter of 2026, I wanted to take this opportunity to update you on the developments taking place at ASP Isotopes Inc. All of our business units are making considerable progress, group revenues are increasing, and three of ou
- SECSEC Form 425 filed by ENDRA Life Sciences Inc.425 - ENDRA Life Sciences Inc. (0001681682) (Subject)
- NEWSJoin the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium CompanyNoble Africa was created to unlock the value of Renergen's Virginia Gas Project through a public company focused on helium and LNGLearn why the Virginia Gas Project is positioned to become one of the world's most strategic helium developments as global supply tightens and demand accelerates DALLAS, TX AND ANN ARBOR, MI / ACCESS Newswire / July 17, 2026 / ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or "ASPI"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or "NDRA"), a pioneer in thermoacoustic biomarker imaging for early detection and
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Other Events8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by ENDRA Life Sciences Inc.SCHEDULE 13D/A - ENDRA Life Sciences Inc. (0001681682) (Subject)
- SECSEC Form 425 filed by ENDRA Life Sciences Inc.425 - ENDRA Life Sciences Inc. (0001681682) (Subject)
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Control of Registrant, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECSEC Form 144 filed by ENDRA Life Sciences Inc.144 - ENDRA Life Sciences Inc. (0001681682) (Subject)
- SECSEC Form 425 filed by ENDRA Life Sciences Inc.425 - ENDRA Life Sciences Inc. (0001681682) (Subject)
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECENDRA Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECSEC Form RW filed by ENDRA Life Sciences Inc.RW - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdateENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today reported financial results for the quarter ended March 31, 2026, and provided a business update. Business Update Initiated Evaluation of Strategic Alternatives On March 25, 2026, the Company announced that its Board of Directors has initiated a process to evaluate strategic alternatives aimed at maximizing shareholder value. ENDRA will continue to execute on its strategic and operating initiatives during the review process, and has not set a timetable for completion of the process. Demonstr
- SECSEC Form S-8 filed by ENDRA Life Sciences Inc.S-8 - ENDRA Life Sciences Inc. (0001681682) (Filer)
- SECSEC Form 10-Q filed by ENDRA Life Sciences Inc.10-Q - ENDRA Life Sciences Inc. (0001681682) (Filer)
- PRENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and ReproducibilityResults confirm accurate and consistent liver steatosis assessment performance across operators, geographies and patient populations, supporting planned regulatory pathway ENDRA Life Sciences Inc. (NASDAQ:NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for the early detection and monitoring of steatotic liver disease (SLD), today announced multi-site clinical validation results for TAEUS® Liver that demonstrate strong concordance with MRI-PDFF, high reproducibility and consistent performance across clinical sites. The analysis combined data from 64 patients in the U.S. and Canada, including an external validation site in London, Ontario, across independen
NDRA FAQ
9 questionsWhat does ENDRA Life Sciences Inc. do?
ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. It develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. The company also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about...What is the latest news on NDRA?
In the last 30 days Quantisnow tracked 3 wire items for NDRA: 1 13D/G filing, 1 earnings update and 1 SEC filing. The most recent was published on November 16, 2026.Is NDRA profitable?
No. ENDRA Life Sciences Inc. reported a net loss of $5.85M for the twelve months ended Sep 30, 2026.How much cash and debt does NDRA have?
ENDRA Life Sciences Inc. reported $1.52M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does NDRA stock trade?
ENDRA Life Sciences Inc. (NDRA) is listed on NASDAQ.What sector and industry is NDRA in?
ENDRA Life Sciences Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did ENDRA Life Sciences Inc. go public?
ENDRA Life Sciences Inc. (NDRA) completed its IPO in 2017.What companies are similar to NDRA?
Notable peers in the same industry include IRTC (iRhythm Holdings Inc.), BFLY (Butterfly Network Inc.). Compare NDRA side-by-side with any of them on Quantisnow.How can I track NDRA on Quantisnow?
Quantisnow aggregates ENDRA Life Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NDRA to receive live email and push alerts on every new disclosure.